Compare · BLCO vs RXST
BLCO vs RXST
Side-by-side comparison of Bausch + Lomb Corporation (BLCO) and RxSight Inc. (RXST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLCO and RXST operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- BLCO is the larger of the two at $5.80B, about 26.7x RXST ($217.3M).
- Over the past year, BLCO is up 18.7% and RXST is down 29.2% - BLCO leads by 48.0 points.
- RXST has been more active in the news (6 items in the past 4 weeks vs 3 for BLCO).
- RXST has more recent analyst coverage (25 ratings vs 18 for BLCO).
- Company
- Bausch + Lomb Corporation
- RxSight Inc.
- Price
- $16.29+1.94%
- $5.26+6.80%
- Market cap
- $5.80B
- $217.3M
- 1M return
- +7.88%
- +11.78%
- 1Y return
- +18.73%
- -29.23%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- 2021
- News (4w)
- 3
- 6
- Recent ratings
- 18
- 25
Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions. It offers intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
RxSight Inc.
RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery. It also offers RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is based in Aliso Viejo, California.
Latest BLCO
- Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate
- Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care
- Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29
- President, Surgical Bonnefoy Luc covered exercise/tax liability with 1,008 shares, decreasing direct ownership by 1% to 87,023 units (SEC Form 4) to satisfy tax liability
- SEC Form SD filed by Bausch + Lomb Corporation
- Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States
- Director Von Eschenbach Andrew C. was granted 15,842 shares, increasing direct ownership by 22% to 86,656 units (SEC Form 4)
- Director Ross Thomas W. Sr. was granted 15,842 shares, increasing direct ownership by 23% to 85,233 units (SEC Form 4)
- Director Robertson Russel C was granted 15,842 shares, increasing direct ownership by 20% to 94,260 units (SEC Form 4)
- Director Paulson John was granted 15,842 shares, increasing direct ownership by 21% to 89,823 units (SEC Form 4)
Latest RXST
- RxSight Inc. filed SEC Form 8-K: Regulation FD Disclosure
- RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer
- RxSight Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- RxSight Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement
- Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
- Director Warner Robert Keith was granted 37,037 shares, increasing direct ownership by 90% to 78,076 units (SEC Form 4)
- Director Palmisano Robert J was granted 37,037 shares, increasing direct ownership by 90% to 78,076 units (SEC Form 4)
- Director Maniar Shweta was granted 37,037 shares, increasing direct ownership by 204% to 55,172 units (SEC Form 4)
- Director Fountain Tamara was granted 37,037 shares, increasing direct ownership by 104% to 72,582 units (SEC Form 4)